Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 26

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 26
---
 microglial cells become activated and cause dysfunction of the other three cells types in the neural unit resulting
in neurodegenerative and neuropsychiatric diseases. Hepatic stellate cells are immunologically active cells that are part of the liver
architecture that support hepatocyte function in health and disease. INB03, LivNate and XPro1595 are the identical drug used in different
therapeutic arenas. INB03 is the name of the drug for cancer targeted applications. XPro1595 in the name of the drug for neurology and
psychiatric indications. LivNate is the name of the drug for treatment of liver diseases.

We believe INKmune, our NK
cell directed therapy, and INB03, our MDSC directed therapy, and XPro1595, our microglial directed therapy and LivNate, our HSC directed
therapy offer unique strategies to improve the response of patients’ innate immune system to their cancer, neurologic and liver
disease respectively. These therapies will use a precision medicine approach to select patients who will benefit from the therapy and
monitor the response to the therapy. For oncology, neither INB03 nor INKmune therapy is cancer specific. The decision to use either INKmune
or INB03 as part of cancer therapies, or with each other, depends on immunologic parameters that can be tested in patients before treatment.
The type of cancer is not important. This means that both therapies can be used to treat patients with a variety of hematologic malignancies
and solid tumors that have the immunologic profile needed to respond. Put simply, we are treating the immune system to attack the patients’
cancer, not targeting the patient’s cancer directly.

We believe that INKmune improves
the ability of the patient’s own NK cells to attack their tumor. INKmune itself will not kill cancer cells. INKmune interacts with
the patient’s NK cells to convert them from inert resting NK cells that ignores the cancer into primed NK cells that kill the cancer
cell. INKmune is a replication incompetent proprietary cell line we have named INB16 that is given to the patient after determining that
i) the patient has adequate NK cells in their circulation and ii) those NK cells are functional when exposed to INKmune in vitro. INKmune
is designed to be given to patients after their immune system has recovered after cytotoxic chemotherapy to target the residual disease
the